Business
Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023
CAMBRIDGE, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical
About this update from Werewolf Therapeutics, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the publication of an abstract summarizing an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida. Details for the abstract and poster presentation are as follows: Abstract Number: 1829 Title: Generation of IL-21 INDUKINE™ molecules for the treatment of cancerSession Category: ImmunologySession Title: Immunomodulatory Agents and Interventions 2Session Date and Time: Monday, April 17, 2023 from 9:00 a.m. - 12:30 p.m.Location: Poster Section 24Poster Board Number: 1 About Werewolf TherapeuticsWerewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We expect to advance WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit www.werewolftx.com. Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risk and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Werewolf’s future operations, prospects, plans, the expected timeline for the clinical development of product cand...